ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

1-ブチル-3-スルファニリル尿素

Carbutamide

HCID 9564
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
339-43-5
標準SMILES
CCCCNC(=O)NS(=O)(=O)c1ccc(N)cc1
InChIKey
VDTNNGKXZGSZIP-UHFFFAOYSA-N
分子式
C11H17N3O3S
平均分子量
271.34 g/mol
単同位体質量
271.09906259

概要

Carbutamide is a member of benzenes and a sulfonamide.

名称と識別子

優先名称
Carbutamide
IUPAC
1-(4-aminophenyl)sulfonyl-3-butylurea
現地名
1-ブチル-3-スルファニリル尿素
英語名
carbutamide
分子式
C11H17N3O3S
分子量
271.34

名称と別名

Carbutamide339-43-5GlybutamideButisulfinaGlucidoralEmedanInvenolGlucofrenDiaboralAminophenurobutaneNorboralOrasulin
名称をさらに表示
オラニルエメダン1-ブチル-3-スルファニリル尿素カルブタミドオラスリンナジサンインベノールU-6987OranilBucarban
BurcolNadisanOranylBukarbanAlentinBucrolInbutonNadizan

データベース識別子

CAS
339-43-5
PubChem CID
9564
DTXSID
DTXSID8022741
ChEMBL
CHEMBL448570
ChEBI
CHEBI:135118
UNII
E3K8P4869P
EC Number
206-424-4
Nikkaji
J5.684G

物性

構造計算による物性補完中

XLogP
1
極性表面積
110 Ų
水素結合供与体数
3
水素結合受容体数
4
回転可能結合数
5
重原子数
18
形式電荷
0
複雑度
356

実験および物理化学的性質

SpringerMaterials PropertiesCrystal structure
LogP · 2 件

log Kow= 1.01

1.18

Color/FormCrystals
Solubility · 2 件

Sol in water at pH 5 to 8.

In water, 535 mg/l @ 37 °C

Melting Point144-145 °C
Collision Cross Section165.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID8022741]

物理化学的性質

融点
144 · 144-145°
比重(密度)
1.284 · 1.2840 (rough estimate)
屈折率
1.663 · 1.6630 (estimate)
貯蔵温度
Refrigerator
溶解性
DMSO(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
5.75 · pKa 5.75(H2O t=25±0.02 I=0.2) (Uncertain)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (97.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Other Safety InformationIMAP assessments - Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: Human health tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Irrit. 2 (97.5%)

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

化学と産業

薬理情報

ATC Code · 2 件

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Mechanism of Action · 1 件

SULFONYLUREAS STIMULATE ISLET TISSUE TO SECRETE INSULIN. ... SULFONYLUREAS CAUSE DEGRANULATION OF THE BETA CELLS, A PHENOMENON ASSOCIATED WITH INCR RATE OF SECRETION OF INSULIN. ...THEY ARE EFFECTIVE IN INSULIN-INDEPENDENT DIABETIC PATIENTS IN WHOM THE PANCREAS RETAINS THE CAPACITY TO SECRETE INSULIN. /SULFONYLUREAS/

Metabolism/Metabolites · 2 件

...IN MAN APPROX ONE-THIRD OF THE EXCRETED DOSE IS REPRESENTED BY THE N-ACETYLATED METABOLITE. LARGE SPECIES VARIATIONS HAVE BEEN DETECTED; THE RABBIT PRODUCES SIGNIFICANT AMT...WHILE MONKEY & DOGS ARE LOW OR VERY LOW ACETYLATORS & MAN OCCUPIES AN INTERMEDIATE POSITION.

THEY ARE HYDROXYLATED IN THE LIVER TO ACTIVE & INACTIVE PRODUCTS WHICH ARE ALMOST TOTALLY EXCRETED IN THE URINE. /SULFONYLUREAS/

MeSH Pharmacological ClassificationSubstances which lower blood glucose levels.
Absorption, Distribution and Excretion · 2 件

THE SULFONYLUREAS ARE READILY ABSORBED FROM THE GI TRACT. THE MOST IMPORTANT DIFFERENCE AMONG THE SULFONYLUREAS, FOR CLINICAL PURPOSE, IS IN THEIR DURATION OF ACTION... /SULFONYLUREAS/_

SULFONYLUREAS ARE LARGELY BOUND TO PLASMA PROTEINS & ARE DISTRIBUTED IN THE EXTRACELLULAR SPACE. /SULFONYLUREAS/

用途と製造

Uses · 2 件

Therap cat: Antidiabetic

MEDICATION (VET)

U.S. Production · 2 件

(1979) NOT PRODUCED COMMERCIALLY IN U.S.

(1981) NOT PRODUCED COMMERCIALLY IN U.S.

Methods of Manufacturing · 2 件

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
色
オフホワイトからペールベージュ
水溶解度
535.2 mg/L · 535.2mg/L(37℃)
EPAの化学物質情報
4 · Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]- (339-43-5)

化学的性質

化学的特性Off-White to Pale Peach Solid

...SODIUM CARBONATE REDUCED...DRUG'S TERATOGENIC & LETHAL ACTION IN RAT.

DRUGS THAT MAY INCR RISK OF HYPOGLYCEMIA FROM SULFONYLUREAS INCL OTHER HYPOGLYCEMIC AGENTS, SULFONAMIDES, PROPRANOLOL, SALICYLATES, CLOFIBRATE, PHENYLBUTAZONE, PROBENECID, DICUMAROL, CHLORAMPHENICOL, MONOAMINE OXIDASE INHIBITORS, & ALCOHOL. /SULFONYLUREAS/

ALCOHOL & SALICYLATES BECAUSE OF THEIR DIRECT HYPOGLYCEMIC ACTION, MAY PRECIPITATE HYPOGLYCEMIC COMA IN PT RECEIVING SULFONYLUREAS. ... PROPRANOLOL, BY INTERFERING WITH GLYCOGENOLYSIS & GLUCAGON RELEASE, ENHANCES THE HYPOGLYCEMIC ACTION OF SULFONYLUREAS. /SULFONYLUREAS/

THE SULFONYLUREA-MEDIATED SECRETION OF INSULIN CAN BE MODIFIED BY CONCOMITANT PERFUSION OF SECOND DRUG THAT DISPLACES SULFONYLUREA IN PANCREAS. THUS, THE DRUG INTERACTION AT THE TARGET ORGAN OR RECEPTOR SITE SHOULD BE UNDERSTOOD TO PROVIDE ADEQUATE DRUG THERAPY.

For more Interactions (Complete) data for 1-BUTYL-3-SULFANILYLUREA (8 total), please visit the HSDB record page.

Human Toxicity ExcerptsFOURTEEN PT TREATED WITH CARBUTAMIDE HAD TRANSIENT HEMIPARESIS. 4 HAD IRREVERSIBLE NEUROLOGIC DEFECTS, & 5 EXPIRED AFTER HYPOGLYCEMIC COMA. NEARLY 70 OF THE EPISODES OCCURRED WITHIN THE FIRST 15 DAYS OF THE SULFONYLUREA TREATMENT.
Non-Human Toxicity Excerpts · 5 件

CARBUTAMIDE...HAS BEEN SHOWN TO BE TOXIC TO THE EYES OF RATS WHEN CHRONICALLY ADMIN AT DOSAGES 5 TO 40 TIMES THOSE EMPLOYED IN TREATMENT OF HUMAN BEINGS. IT HAS CAUSED OPACIFICATION OF LENS & CORNEA, VASCULARIZATION OF CORNEA, & POSTERIOR SYNECHIAS, USUALLY IN 8-24 MO. ... IN DOGS SIMILAR TREATMENT HAS NOT AFFECTED EYES.

...CLEFT PALATE, EYE DEFECTS & GENERALIZED EDEMA /WAS FOUND/ IN RAT FETUSES WHOSE MOTHERS RECEIVED 500 MG/DAY FOR 1, 2 OR 3 DAYS DURING THE EMBRYONIC PERIOD.

...800 MG/KG FROM 1ST THROUGH 12TH DAY /OF GESTATION/ IN RATS PRODUCED 10-33% MALFORMED FETUSES. MAJORITY OF DEFECTS INVOLVED EYE & INCL ABSENCE OF OPTIC NERVE. SOME NERVOUS SYSTEM DEFECTS...REPORTED. ... /ANOTHER INVESTIGATOR/...CAUSED CLEFT PALATES & HYDROCEPHALUS WITH THIS SUBSTANCE IN RATS.

CARBUTAMIDE WAS ADMIN PARENTERALLY IN DOSES OF 100 MG/KG BODY WT & WAS WELL TOLERATED. FOLLOWING TREATMENT ON DAYS 4, 5, & 6 NO ABNORMALITIES WERE SEEN IN 6 1/2 DAY BLASTOCYSTS. NO EFFECT ON FETAL DEVELOPMENT.

For more Non-Human Toxicity Excerpts (Complete) data for 1-BUTYL-3-SULFANILYLUREA (13 total), please visit the HSDB record page.

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

tsca
TSCA listed
毒性
LD50 s.c. in mice: 3 g/kg (Haack, Hagedorn)
有毒物質データの
339-43-5(Hazardous Substances Data)

...from butylurea and sulfanilamide: Samaniego, Spanish patent 229,696 (1956), CA 51, 7413 (1957); Haack, Hagedorn, US patent 2,907,692 (1959 to Boehringer, Mann). Alternate route: Haack, Hagedorn, US patent 2,997,375 (1961 to Boehringer, Mann).

REACTION OF BUTYLUREA WITH SULFANILAMIDE

General Manufacturing InformationBenzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: INACTIVE

応用分野

使用Antidiabetic.

上流・下流製品情報

上流原料

イソチオシアン酸ブチル亜硝酸ナトリウム